XASX
4DX
Market cap87mUSD
Jun 13, Last price
0.29AUD
1D
0.00%
1Q
-21.62%
IPO
-25.64%
Name
4DMedical Ltd
Chart & Performance
Profile
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2015‑12 | |
Income | |||||||||
Revenues | 3,754 1,230.44% | 282 -73.24% | 1,054 385.90% | ||||||
Cost of revenue | 31,098 | 29,182 | 26,344 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (27,344) | (28,900) | (25,290) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (4,417) | 323 | 43 | ||||||
Tax Rate | |||||||||
NOPAT | (22,927) | (29,224) | (25,333) | ||||||
Net income | (35,979) 14.36% | (31,460) 27.92% | (24,593) 14.81% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 35,000 | 42,558 | |||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 945 | 933 | 1,100 | ||||||
Long-term debt | 9,297 | 9,344 | 11,378 | ||||||
Deferred revenue | 718 | ||||||||
Other long-term liabilities | 15,240 | 186 | 105 | ||||||
Net debt | (20,365) | (59,344) | (38,681) | ||||||
Cash flow | |||||||||
Cash from operating activities | (30,867) | (22,653) | (25,269) | ||||||
CAPEX | (156) | (731) | (3,078) | ||||||
Cash from investing activities | (40,040) | (1,614) | (3,501) | ||||||
Cash from financing activities | 31,937 | 42,728 | (995) | ||||||
FCF | (22,416) | (28,130) | (32,866) | ||||||
Balance | |||||||||
Cash | 30,606 | 69,576 | 51,115 | ||||||
Long term investments | 45 | 45 | |||||||
Excess cash | 30,418 | 69,607 | 51,107 | ||||||
Stockholders' equity | 70,927 | 71,460 | 59,511 | ||||||
Invested Capital | 61,588 | 7,178 | 14,706 | ||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 327,079 | 300,014 | 294,508 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (23,279) | (26,335) | (23,794) | ||||||
EV/EBITDA | |||||||||
Interest | 264 | 7 | 180 | ||||||
Interest/NOPBT |